Published in AIDS Weekly, February 2nd, 2004
The 22 researchers said that there are no "persuasive data" to suggest that the experimental vaccine, a combination of ALVAC +gp120, would help to protect against HIV infection. The research trial involves 16,000 volunteers in Thailand.
The scientists, writing in Science, said that a clinical trial of similar design was scheduled to be conducted in the United States by the HIV Vaccine Trials Network (HVTN), the world's largest consortium of AIDS vaccine scientists and clinicians, but was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.